Difference between revisions of "Periampullary adenocarcinoma"
Jump to navigation
Jump to search
m |
|||
| Line 14: | Line 14: | ||
<div style="background-color: #deebf6; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Variant |limit=10000|format=sum}} [[Tutorial#Variants|variants]] on this page</b></font></div> | <div style="background-color: #deebf6; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Variant |limit=10000|format=sum}} [[Tutorial#Variants|variants]] on this page</b></font></div> | ||
|} | |} | ||
| + | <big>Note: there is some overlap, especially in the earlier literature, between treatment regimens for periampullary adenocarcinoma and those for '''[[pancreatic cancer|pancreatic adenocarcinoma]]''', '''[[cholangiocarcinoma]]''', and gallbladder cancer; please see those pages for additional regimens.</big> | ||
{{TOC limit|limit=3}} | {{TOC limit|limit=3}} | ||
| − | |||
| − | |||
=Guidelines= | =Guidelines= | ||
==[http://www.esmo.org/ ESMO]== | ==[http://www.esmo.org/ ESMO]== | ||
Revision as of 14:24, 6 May 2019
| Page editor | Section editor | ||
|---|---|---|---|
 |
Ivy Abraham, MD University of Illinois at Chicago Chicago, IL |
 |
Neeta K. Venepalli, MD, MBA University of Illinois at Chicago Chicago, IL |
0 regimens on this page
0 variants on this page
|
Note: there is some overlap, especially in the earlier literature, between treatment regimens for periampullary adenocarcinoma and those for pancreatic adenocarcinoma, cholangiocarcinoma, and gallbladder cancer; please see those pages for additional regimens.
Guidelines
ESMO
- 2016: Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. PubMed
NCCN
Adjuvant therapy
Observation
| back to top |
Regimen
| Study | Evidence | Comparator | Efficacy |
|---|---|---|---|
| Takada et al. 2002 | Phase III (C) | 5-FU & Mitomycin | Seems not superior |
| Neoptolemos et al. 2012 (ESPAC-3) | Phase III (C) | 1. 5-FU & Leucovorin 2. Gemcitabine |
Seems not superior |
No adjuvant therapy.
Preceding treatment
References
- Takada T, Amano H, Yasuda H, Nimura Y, Matsushiro T, Kato H, Nagakawa T, Nakayama T; Study Group of Surgical Adjuvant Therapy for Carcinomas of the Pancreas and Biliary Tract. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer. 2002 Oct 15;95(8):1685-95. link to original article PubMed
- ESPAC-3: Neoptolemos JP, Moore MJ, Cox TF, Valle JW, Palmer DH, McDonald AC, Carter R, Tebbutt NC, Dervenis C, Smith D, Glimelius B, Charnley RM, Lacaine F, Scarfe AG, Middleton MR, Anthoney A, Ghaneh P, Halloran CM, Lerch MM, Oláh A, Rawcliffe CL, Verbeke CS, Campbell F, Büchler MW; European Study Group for Pancreatic Cancer. Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial. JAMA. 2012 Jul 11;308(2):147-56. Erratum in: JAMA. 2012 Nov 14;308(18):1861. link to original article PubMed